Oppenheimer raised the firm's price target on Incyte to $90 from $84 and keeps a Perform rating on the shares. The firm notes the company reported Q1 results boasting both top-line and bottom-line beats, while FY26 guidance of was maintained. Generally, Oppenheimer sees Incyte's updates as relatively straightforward while it sees focus shifting to clinical readouts expected this year, specifically in oncology.
